Cargando…
Hypouricemic effect and safety of febuxostat used for prevention of tumor lysis syndrome
PURPOSE: We evaluated the efficacy and safety of febuxostat, a non-purine xanthine oxidase inhibitor, used for prevention of hyperuricemia associated with tumor lysis syndrome (TLS). METHODS: Records of adult patients with newly diagnosed or relapsed hematologic malignancies who received febuxostat...
Autores principales: | Maie, Koichiro, Yokoyama, Yasuhisa, Kurita, Naoki, Minohara, Hideto, Yanagimoto, Shintaro, Hasegawa, Yuichi, Homma, Masato, Chiba, Shigeru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164671/ https://www.ncbi.nlm.nih.gov/pubmed/25279293 http://dx.doi.org/10.1186/2193-1801-3-501 |
Ejemplares similares
-
Prolonged Survival of a Refractory Acute Myeloid Leukemia Patient after a Third Hematopoietic Stem Cell Transplantation with Umbilical Cord Blood following a Second Relapse
por: Lee, Suk-young, et al.
Publicado: (2014) -
Febuxostat Attenuates Renal Damage besides Exerting Hypouricemic Effect in Streptozotocin-Induced Diabetic Rats
por: Ran, Jianmin, et al.
Publicado: (2017) -
Durable Leukemic Remission and Autologous Marrow Recovery with Random Chromosomal Abnormalities after Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia
por: Nishikii, Hidekazu, et al.
Publicado: (2019) -
An Unprecedented Case of p190 BCR-ABL Chronic Myeloid Leukemia Diagnosed during Treatment for Multiple Myeloma: A Case Report and Review of the Literature
por: Miki, Kosuke, et al.
Publicado: (2018) -
Clinical significance of disease‐specific MYD88 mutations in circulating DNA in primary central nervous system lymphoma
por: Hattori, Keiichiro, et al.
Publicado: (2017)